')">

Market access update

ASH Annual Meeting 2022

Join the team from PRMA Consulting, part of Fishawack Health, in New Orleans, Louisiana, 1013 December 2022, for the ASH Annual Meeting, one of the leading events in malignant and classical hematology.

Showcasing end-to-end Policy, Access, Value, and Evidence services at the ASH Annual Meeting

PRMA Consulting is looking forward to attending the 64th ASH Annual Meeting to showcase our combined Policy, Access, Value, and Evidence services for assets in malignant and classical hematology.

 


Leverage our experience in cell and gene therapies, small molecules, bi-specifics, immuno-oncology, and monoclonal antibodies

As global healthcare consulting experts, we partner with leading life sciences companies, health plans, providers, and investors to bring innovative data, technology-driven solutions, and experienced-based insights to today’s most complex healthcare challenges.

 

 

We have in-depth understanding in key therapeutic areas including: multiple myeloma, acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, Hodgkin’s lymphoma, follicular lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, and myelodysplastic syndromes.

 

From early pipeline to patient access, we provide best in class solutions for hemato-oncology market access challenges

In a rapidly evolving environment where stakeholders are becoming more evidence hungry and value aware, we provide best-in-class data-driven solutions to complex healthcare challenges. Our Policy, Access, Value, and Evidence consultancy delivers policy, market access, and HEOR solutions for global, regional, and local stakeholders in the US, Europe, APAC, and LatAm.    


Digital applications for HEOR and market access at the ASH Annual Meeting  

The ASH Annual Meeting provides a perfect opportunity to examine the digital transformation of your market access process. Our expert team will be in New Orleans to help you evaluate how digital applications will help you realize your market access vision.

hēRo3 has revolutionized HEOR modeling, especially for pipeline assets, enabling rapid value analytics to be conducted for development candidates. In turn, it plays a key role in promoting the strategic design of clinical development programs and HEOR evidence generation plans. The novel technology is used by more than a dozen of the top 40 biopharmaceutical companies and has helped usher in an era of rapid HEOR analytics for pipeline assets. Book a virtual demonstration.
PRMA Healthcheck® helps you to maximize the value of your asset portfolio at all stages of development. It drives a systematic and robust assessment of the market access risks and opportunities based on treatment landscapes, pricing potential, and evolving payer needs. Book a virtual demonstration.
PRMA Navigator® helps you empower your affiliates to efficiently and effectively deliver high-quality multiple HTA and other payer submissions by maximizing the use of global materials, saving time and resources to focus on getting the strategy right. Book a virtual demonstration.
PRMA Tracker® tracks the evolving HTA and P&R landscape for key competitors or products of interest to ensure key learnings from payer assessments are captured and the strategic implications for your asset are considered. 
Book a virtual demonstration.

 


You have a vision; we are the consulting partner that will get you there

Our team will help you bring out the best in your asset, using their extensive market access and disease area experience, and through the award-winning PRMA Consulting suite of digital applications.

We would be delighted to have a confidential conversation about your market access needs, please contact us to arrange an appointment.

FREE Ebook

Reinventing product and portfolio value for the biopharmaceutical industry

Free download

We respect your privacy. Cookie policy.

Latest insights

Navigating the cell and gene therapy market ...

Market access careers in the Asia-Pacific region: ...

The lasting impact of the Inflation Reduction ...